Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
about
Vaccines for preventing typhoid feverVaccines for preventing typhoid feverA mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trialEntirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune ResponsesRethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areasDevelopment of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharidePopulation-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in AfricaContribution of the stg fimbrial operon of Salmonella enterica serovar Typhi during interaction with human cellsVi polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses.Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005.Vi Capsular Polysaccharide Produced by Recombinant Salmonella enterica Serovar Paratyphi A Confers Immunoprotection against Infection by Salmonella enterica Serovar Typhi.B7-H1 (programmed cell death ligand 1) is required for the development of multifunctional Th1 cells and immunity to primary, but not secondary, Salmonella infectionPhysical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugatesFifth Percentile Cutoff Values for Antipneumococcal Polysaccharide and Anti-Salmonella typhi Vi IgG Describe a Normal Polysaccharide ResponsePhase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccineRe-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young childrenSafety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa.Travel vaccines and elderly persons: review of vaccines available in the United States.The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of Salmonella enterica serotype Typhi.Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.Synthesis and some immunologic properties of an O-acetyl pectin [poly(1-->4)-alpha-D-GalpA]-protein conjugate as a vaccine for typhoid fever.Early eradication of persistent Salmonella infection primes antibody-mediated protective immunity to recurrent infection.Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates.The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines.Evaluation of vaccines against enteric infections: a clinical and public health research agenda for developing countriesLocal and systemic antibody responses to dextran-cholera toxin B subunit conjugatesCharacterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhiSynthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetylsSynthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linkerVaccination Method Affects Immune Response and Bacterial Growth but Not Protection in the Salmonella Typhimurium Animal Model of Typhoid.Typhoid vaccination - UpdateFunctional Activity of Antibodies Directed towards Flagellin Proteins of Non-Typhoidal Salmonella.MyD88-dependent pro-inflammatory activity in Vi polysaccharide vaccine against typhoid promotes Ab switching to IgG.Capsular polysaccharide-protein conjugate vaccines and intravenous immunoglobulins.Whole Genome Sequence Analysis of Salmonella Typhi Isolated in Thailand before and after the Introduction of a National Immunization Program.Capsule-mediated immune evasion: a new hypothesis explaining aspects of typhoid fever pathogenesis
P2860
Q24201238-84DB5C96-80BB-4ACB-9B2F-A730B7E7E3EEQ24244406-AE21C5D7-3B1C-40EA-B42E-42AFD20DE9F4Q24811133-777E8B4B-B371-409E-ACA7-CD534DA75C2FQ26746887-5A57693A-E6CF-48B5-9A5B-ED7FF82982C8Q28308143-C38101A1-8E2E-4E5F-8E8E-5631F337674EQ28394220-1953C4A0-A20E-4618-B150-9C494FE0930FQ28478975-9DE5D9FF-3D0D-48C2-9022-478F2688D023Q28756095-3D57011A-6F00-444E-BA0F-7D998A4C78A7Q30448411-9CAB5D63-3D1C-49D6-BB35-11B3D96119BFQ31121277-76277C1D-2719-44DE-9C10-9532A5983FCBQ33593401-209A6F6B-BF94-469A-BEF1-68CDF07D30ABQ33597276-64B07E41-24B4-407A-B04C-2F33212EA204Q33613531-D1D6207A-7BE6-4F4D-B520-59DA229B90C7Q33665323-894F0827-97D2-44A4-9039-75DE4DB39260Q33666510-E65CAC1B-35DC-4011-A6C6-C839FF4DEFC6Q33797264-1BE6DB43-CEEF-4345-A484-8249B48B2E6EQ34002415-1977D19B-B3FA-49B9-862D-E439542CE4F1Q34003500-1E341DD0-FD27-4762-B314-547C8DD04AEBQ34007802-99380191-FA4E-4D8E-B186-67269A1EF265Q34008449-A2834E0B-5773-4548-8D98-E1FDFEDCCA51Q34275116-44C1B8CF-6784-49BD-A8CF-07356965706FQ34392982-95064B0C-6DAE-4B23-BF25-1F7A6D32B3E2Q34529614-C61A826C-4A92-42D6-B476-79404C7DDC21Q34541176-4C59B90B-A8B9-44EF-8289-DCC1A8F1BFDEQ34548668-E71337B5-7B4F-46B2-9EAE-8D4B94DFF9C0Q34669382-D73B14B3-3D79-4315-BEE8-00C0F3555D39Q34760675-03A2B0DE-0E9A-47EE-8A42-52E7A5A30C0CQ35066191-998FA873-822B-45AE-9C89-F1C905B5EF49Q35137102-35E55280-EE53-4F21-97F8-D46D6D7EA323Q35413377-F8B1E4BA-81BC-4889-A053-B7BF32E7B90CQ35450564-AFAD56BE-9E83-41FA-B486-0A89A9E10588Q35505761-C9EC7BB7-9C0C-4589-9139-ECF0BBB1B359Q35548581-52C9E58C-CF24-47F0-9630-FC5D452C3E79Q35824212-F0ED1EE0-1157-4785-B80E-B51CCBD66657Q35892982-06EA45BE-CB62-4C6F-9EF4-4762216573EAQ35964671-1F57EEA4-48B7-4A89-9031-93D0D204DE87Q36066380-F61480E1-C0C5-41B0-A9A0-9D3F8D871B92Q36181172-DF409B38-D330-4CBC-9A5F-86812CAE5D2EQ36242433-AC342F16-0B3C-4903-BFB6-322F5CEC6C70Q36348390-D6B9A7D8-3C60-48CA-B840-4AB0D3AD6438
P2860
Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
@en
type
label
Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
@en
prefLabel
Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
@en
P2093
P1433
P1476
Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
@en
P2093
H J Koornhof
I T Gilbertson
J B Robbins
K P Klugman
R Schneerson
P304
P356
10.1016/S0140-6736(87)91316-X
P407
P577
1987-11-01T00:00:00Z